Profilo
Joanne Palmer is currently the Head of Clinical Operations at Convergence Pharmaceuticals Ltd.
and the Chief Development Officer at Eliem Therapeutics, Inc. She previously worked at GSK Plc as a Principal.
Posizioni attive di Joanne Palmer
| Società | Posizione | Inizio |
|---|---|---|
| ELIEM THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | 06/10/2010 |
Precedenti posizioni note di Joanne Palmer
| Società | Posizione | Fine |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| GSK PLC | Health Technology |
| ELIEM THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Joanne Palmer
